AGIX - As I postulated, AGIX bears watching. The results for the just announced ANDES trial indicate that there is probably still a liver tox issue at the lower doses.
BUT - they also may have found a screen for the patients who are likely to develop the liver tox. I would want to see details before getting on board conceptually - but the management team is better than the average biotech team so there is some chance they have a real screen. In which case this could be a blockbuster since it also has hard cardiac data.
Lots of ifs, but definitely interesting.
PS Bummer that it bounced so high on a result that was a fait accompli and I wasn't in - there was never really much doubt about the efficacy result after the interim indicated that their choice of trial sites wasn't suicidal. Apparently the market had still been in doubt - or maybe it is the new possibility of a screen that caused the bounce - just plain odd.
PPS Note on trial sites - as predicted, the Eastern Europe trial site was a bust. It was the other locations (e.g. India and S. Africa) that kept the trial working. Good info going forward.
News 
Market Data 
Discover 
AI
